Immutep Investors Face Class Action After TACTI-004 Trial Failure

The legal action, spearheaded by Pomerantz LLP, centers on allegations of securities fraud and unlawful business practices by Immutep leadership. The controversy stems from a March 13, 2026, announcement regarding the TACTI-004 Phase III study. The Independent Data Monitoring Committee recommended halting the trial for eftilagimod alfa after an interim futility analysis revealed the treatment failed to meet necessary benchmarks in first-line non-small cell lung cancer patients.

Following the disclosure, Immutep's American Depositary Receipt price plummeted by $2.27, closing at just $0.48. Shareholders wishing to participate in the class action must file their motions for lead plaintiff status by July 6, 2026. Interested parties are directed to contact Danielle Peyton at Pomerantz LLP to review the complaint and provide records of their share acquisitions.